Responses
Regular and Young Investigator Award Abstracts
Cellular Therapies
235 Preclinical evaluation and anti-tumor activity of AZD6422, a CLDN18.2 targeting armored CAR-T for gastric, esophageal and pancreatic cancers
Compose a Response to This Article
Other responses
No responses have been published for this article.
